Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. Casgevy uses the novel CRISPR gene-editing technology to modify patients’ blood cells and transplant the modified cells back into the bone marrow, triggering an increase in the production of hemoglobin, according to the FDA. The most common side effects were mouth sores, fever caused by a low level of white blood cells and decreased appetite, the FDA said. That’s how much CRISPR Therapeutics stock rose last year on the heels of regulatory developments in the field of CRISPR technology. Further ReadingMORE FROM FORBES FDA Approves First Crispr Treatment That Might Cure Sickle Cell

Source: Forbes January 17, 2024 19:58 UTC